Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596570 | 0.86 | HDAC1 (0.57) | HDAC1HDAC6POLBTDP1ALDH1A1 | |
| SCHEMBL3601082 | 0.83 | HDAC6 (0.66) | HDAC1HDAC6POLBTDP1ALDH1A1 | |
| SCHEMBL4080378 | 0.82 | POLB (0.69) | HDAC1HDAC6POLBTDP1ALDH1A1 | |
| SCHEMBL3598797 | 0.82 | HDAC1 (0.56) | HDAC1HDAC6POLBTDP1ALDH1A1 | |
| SCHEMBL3612223 | 0.81 | HDAC6 (0.83) | HDAC1HDAC6POLBTDP1 | |
| SCHEMBL6121071 | 0.80 | HDAC1 (0.59) | HDAC1HDAC6POLBTDP1ALDH1A1 | |
| SCHEMBL3611422 | 0.80 | HDAC6 (0.62) | HDAC1HDAC6POLBTDP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6123175 | 0.79 | HDAC1 (0.57) | HDAC1HDAC6POLBTDP1ALDH1A1 | |
| SCHEMBL3608439 | 0.78 | HDAC6 (0.60) | HDAC1HDAC6POLBTDP1ALDH1A1 | |
| SCHEMBL3612530 | 0.77 | HDAC6 (0.62) | HDAC1HDAC6POLBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | claimed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | HDAC1 307/4885HDAC6 90/4885POLB 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.